一种基于Caco-2细胞单层膜的筛选抵抗特定代谢性疾病益生菌的模型

工程（英文） ›› 2023, Vol. 25 ›› Issue (6) : 222 -233. DOI: 10.1016/j.eng.2022.02.014

研究论文

刘阳 ^a^,^b ,
彭江 ^a^,^b ,
朱诗雅 ^a^,^b ,
于雷雷 ^a^,^b ,
田丰伟 ^a^,^b ,
赵建新 ^a^,^b ,
张灏 ^a^,^b^,^c^,^d ,
陈卫 ^a^,^b^,^c ,
翟齐啸 ^a^,^b

作者信息 +

A Screening Model for Probiotics Against Specific Metabolic Diseases Based on Caco-2 Monolayer Membrane

Yang Liu ^a^,^b ,
Jiang Peng ^a^,^b ,
Shiya Zhu ^a^,^b ,
Leilei Yu ^a^,^b ,
Fengwei Tian ^a^,^b ,
Jianxin Zhao ^a^,^b ,
Hao Zhang ^a^,^b^,^c^,^d ,
Wei Chen ^a^,^b^,^c ,
Qixiao Zhai ^a^,^b

Author information +

文章历史 +

PDF (4183K)

摘要

最近的研究揭示了益生菌在缓解与肠道屏障功能障碍相关的代谢疾病方面的潜力。然而，目前还没有一种能高效筛选抵抗特定代谢疾病益生菌菌株的模型。本研究采用肿瘤坏死因子（TNF-α）和酒精处理的Caco-2细胞单层膜模型，评价了139株乳杆菌在体外对肠道屏障功能的影响。然后，我们选择了11株对肠道屏障具有不同调节能力的乳杆菌菌株，进一步在体内评价了它们对卵巢切除引起的骨质疏松症或慢性酒精性肝损伤的作用效果。体外细胞模型和体内动物模型数据的关联性分析显示，两种疾病模型下的Pearson系数分别为0.82和－0.97，表明使用体外细胞模型模拟益生菌在体内的保护作用是可靠的。本研究建立了一种基于Caco-2细胞单层膜模型的体外方法，用于高效筛选可以抵抗特定代谢疾病（如骨质疏松症和慢性酒精性肝病）的益生菌。

Abstract

Recent studies have revealed the potency of probiotics in alleviating metabolic diseases associated with intestinal barrier dysfunction. However, an efficient model for screening probiotic strains against specific metabolic diseases has not been well developed. In the present study, a Caco-2 cell monolayer membrane model treated with tumor necrosis factor (TNF-α) or alcohol was used to evaluate the effect of 139 Lactobacillus strains on intestinal barrier function in vitro. We then selected 11 Lactobacillus strains with different regulatory abilities on the gut barrier to determine their effect against ovariectomy-induced osteoporosis or chronic alcoholic liver injury in vivo. Our results showed that the Pearson coefficient between the data of cell and animal models were 0.82 and −0.97 for the protection of probiotics against osteoporosis and alcoholic liver disease, respectively, suggesting the reliability of the cell model to simulate the in vivo protective effects of probiotics. This study established a potential in vitro approach based on a Caco-2 cell monolayer membrane model for the efficient screening of potential probiotics against specific metabolic diseases such as osteoporosis and chronic alcoholic liver disease.